Tectonic Therapeutic, Inc.
TECX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.83 | -0.31 | -0.45 | 0.19 |
| FCF Yield | -6.12% | -3.97% | -4.31% | -2.46% |
| EV / EBITDA | -1.21 | -4.60 | -0.02 | -46.02 |
| Quality | ||||
| ROIC | -8.14% | -8.17% | -5.98% | -9.53% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.94 | 0.41 | 0.82 | 1.36 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | -21.86% | -12.48% | 22.08% | 14.85% |
| Safety | ||||
| Net Debt / EBITDA | 12.21 | 15.30 | 19.56 | 11.65 |
| Interest Coverage | 1,563.57 | -1,313.65 | -914.90 | -635.95 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -742.24 | -1,563.50 | -172.91 |